ANA
LLUCH HERNANDEZ
EMÉRITO/A UNIVERSIDAD
Emilio
Alba
Publicacions en què col·labora amb Emilio Alba (37)
2023
-
Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis
International Journal of Molecular Sciences, Vol. 24, Núm. 1
-
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis
Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 941-958
-
The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review
Clinical and Translational Oncology, Vol. 25, Núm. 2, pp. 417-428
2022
-
Role of germline variants in the metastasis of breast carcinomas
Oncotarget, Vol. 13, Núm. 1, pp. 843-862
-
The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview
Clinical and Translational Oncology, Vol. 24, Núm. 9, pp. 1744-1754
2019
-
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Frontiers in Oncology, Vol. 9, Núm. APR
-
Detection of TP53 and PIK3CA mutations in circulating tumor DNA using next-generation sequencing in the screening process for early breast cancer diagnosis
Journal of Clinical Medicine, Vol. 8, Núm. 8
2018
-
Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study
European Journal of Cancer, Vol. 94, pp. 199-205
-
Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556
-
Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
Oncotarget, Vol. 9, Núm. 41, pp. 26406-26416
2017
-
18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial
Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441
-
A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse
Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044
-
Critically short telomeres and toxicity of chemotherapy in early breast cancer
Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482
2016
-
High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer
Oncologist, Vol. 21, Núm. 2, pp. 150-155
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
2015
-
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
Annals of Oncology, Vol. 26, Núm. 7, pp. 1280-1291
2014
-
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541
-
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: Results from the GEICAM/2006-14 trial
British Journal of Cancer, Vol. 110, Núm. 5, pp. 1139-1147
2013
-
Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 13, Núm. 3, pp. 381-391
-
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: A pooled analysis
Breast Cancer Research, Vol. 15, Núm. 6